GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Publisher
Person/Organisation
Language
Years
FID
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Novel ring transformation of quinolines to indole derivatives in two steps via 1,4-dihydroquinoline derivatives
    Elsevier BV ; 2003
    In:  Tetrahedron Letters Vol. 44, No. 33 ( 2003-08), p. 6241-6243
    Details
    In: Tetrahedron Letters, Elsevier BV, Vol. 44, No. 33 ( 2003-08), p. 6241-6243
    Type of Medium: Online Resource
    ISSN: 0040-4039
    URL: Article
    DOI: 10.1016/S0040-4039(03)01552-1
    RVK:
    VA 7560
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2003
    detail.hit.zdb_id: 2007074-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Two Distinct Novel Splice Site Mutations in a Compound Heterozygous Patient with Protein S Deficiency
    Georg Thieme Verlag KG ; 1997
    In:  Thrombosis and Haemostasis Vol. 77, No. 01 ( 1997), p. 014-020
    Details
    In: Thrombosis and Haemostasis, Georg Thieme Verlag KG, Vol. 77, No. 01 ( 1997), p. 014-020
    Abstract: Genetic analysis revealed two distinct novel splice site mutations in a compound heterozygous patient with protein S deficiency. The paternal mutation was a G-to-T transition at position -1 of the acceptor splice site of intron N (Mutation I), and the maternal mutation was a G-to-C transversion at position -1 of the donor splice site of intron C (Mutation II). Both splice site mutations decreased the mutated mRNA accumulation to the same extent, approximately 40% of the normal mRNA. However, the mutations were associated with different phenotypical expressions: the paternal mutant protein S was not detected in vivo, while the maternal mutant protein S was present in the plasma in reduced quantity. Because Mutation I caused a cryptic splicing in the mutated mRNA, resulting in a reading frameshift and premature termination, the predicted mutant protein S might be highly unstable. In contrast, Mutation II led to the substitution of Val46 by Leu, which might be much less deleterious for the synthesis, secretion and stability of the predicted mutant protein S. It was supposed that the different post-translational metabolisms produced the distinct phenotypical expressions of the mutations.
    Type of Medium: Online Resource
    ISSN: 0340-6245 , 2567-689X
    URL: Article
    DOI: 10.1055/s-0038-1655729
    Language: English
    Publisher: Georg Thieme Verlag KG
    Publication Date: 1997
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR - ABL –Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group
    American Society of Clinical Oncology (ASCO) ; 2006
    In:  Journal of Clinical Oncology Vol. 24, No. 3 ( 2006-01-20), p. 460-466
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 24, No. 3 ( 2006-01-20), p. 460-466
    Abstract: A novel therapeutic approach is urgently needed for BCR-ABL–positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib. Patients and Methods A phase II study of imatinib-combined chemotherapy was conducted for newly diagnosed BCR-ABL–positive ALL in adults. Eighty patients were entered into the trial between September 2002 and January 2005. Results Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%. The profile and incidence of severe toxicity were not different from those associated with our historic chemotherapy-alone regimen. Relapse occurred in 20 patients after median CR duration of 5.2 months. Allogeneic hematopoietic stem-cell transplantation (HSCT) was performed for 49 patients, 39 of whom underwent transplantation during their first CR. The 1-year event-free and overall survival (OS) rates were estimated to be 60.0%, and 76.1%, respectively, which were significantly better than those for our historic controls treated with chemotherapy alone (P 〈 .0001 for both). Among the current trial patients, the probability for OS at 1 year was 73.3% for those who underwent allogeneic HSCT, and 84.8% for those who did not. Conclusion Our results demonstrated that imatinib-combined regimen is effective and feasible for newly diagnosed BCR-ABL–positive ALL. Despite a relatively short period of observation, a major potential of this treatment is recognized. Longer follow-up is required to determine its overall effect on survival.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2005.03.2177
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2006
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Experimental Lung Injury Induced by Trimellitic Anhydride Inhalation on Guinea Pigs
    S. Karger AG ; 1991
    In:  International Archives of Allergy and Immunology Vol. 96, No. 2 ( 1991), p. 119-127
    Details
    In: International Archives of Allergy and Immunology, S. Karger AG, Vol. 96, No. 2 ( 1991), p. 119-127
    Abstract: Trimellitic anhydride (TMA) causes lung injury by inhalation exposure in humans. In order to investigate more precisely the mechanism of lung injury by TMA, an experimental animal model of TMA-induced lung injury was established. Guinea pigs were intramuscularly injected with trimellitylated bovine serum albumin (TM BSA) with complete Freund’s adjuvant (CFA). Appreciable amounts of antibodies against TM epitopes were detected in the sera of these animals. Guinea pigs that were passively sensitized with anti-TM antisera as well as the actively immunized animals developed hemorrhagic pneumonitis after TMA inhalation. It is well recognized that hyperimmune antisera of guinea pigs contain two subclasses of IgG antibodies, IgG1 and IgG2, which are known as homocytotropic and heterocytotropic antibodies, respectively. To determine the role of these antibodies in the airway injury with alveolar hemorrhages, they were isolated by gel filtration and by ion exchange column chromatography, and the guinea pigs that were sensitized with each of these antibodies were exposed to TMA inhalation. The extent of lung injury in these animals was quantitatively determined by the measurements of lung extravasation of Evans blue dye injected intravenously after TMA inhalation. Significant increases in the extravasation of dye were observed in both animal groups sensitized with IgG1 and IgG2 antibodies. In addition, results obtained with heat-treated antisera and IgG1 antibody did not significantly differ from those obtained with untreated samples. These results suggest that the lung injury resulting from TMA inhalation exposure can be induced with humoral antibodies, not only IgG1 but also IgG2, and that at least two types of allergic reactions are involved in the pathogenesis of lung injury.
    Type of Medium: Online Resource
    ISSN: 1018-2438 , 1423-0097
    URL: Article
    DOI: 10.1159/000235482
    RVK:
    XA 49650
    Language: English
    Publisher: S. Karger AG
    Publication Date: 1991
    detail.hit.zdb_id: 1482722-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    5th Japanese Association of Hepato-Biliary-Pancreatic Surgery : October 14?15, 1993, Arcadia Ichigaya, Tokyo, Japan President: Fujio Hanyu
    Springer Science and Business Media LLC ; 1993
    In:  Journal of Hepato-Biliary-Pancreatic Surgery Vol. 1, No. 1 ( 1993-2), p. 42-104
    Details
    In: Journal of Hepato-Biliary-Pancreatic Surgery, Springer Science and Business Media LLC, Vol. 1, No. 1 ( 1993-2), p. 42-104
    Type of Medium: Online Resource
    ISSN: 0944-1166 , 1436-0691
    URL: Article
    DOI: 10.1007/BF01235934
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 1993
    detail.hit.zdb_id: 2536390-6
    detail.hit.zdb_id: 1473162-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Direct carrier detection in hemophilia B kindreds: Use of modified primers (mutagenic primers) for enzymatic amplification of the factor IX gene
    Elsevier BV ; 1991
    In:  Thrombosis Research Vol. 63, No. 3 ( 1991-08), p. 355-361
    Details
    In: Thrombosis Research, Elsevier BV, Vol. 63, No. 3 ( 1991-08), p. 355-361
    Type of Medium: Online Resource
    ISSN: 0049-3848
    URL: Article
    DOI: 10.1016/0049-3848(91)90138-M
    Language: English
    Publisher: Elsevier BV
    Publication Date: 1991
    detail.hit.zdb_id: 1500780-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Synthesis of 2-Imino-3-[1-(b-D-ribofuranosyl)oxo]-1H,5H-1,5-benzodiazepine through Condensation of o-Phenylenediamine with Formylisoxazole Glycoside
    The Japan Institute of Heterocyclic Chemistry ; 1999
    In:  HETEROCYCLES Vol. 51, No. 4 ( 1999), p. 803-
    Details
    In: HETEROCYCLES, The Japan Institute of Heterocyclic Chemistry, Vol. 51, No. 4 ( 1999), p. 803-
    Type of Medium: Online Resource
    ISSN: 0385-5414
    URL: Article
    DOI: 10.3987/COM-98-8452
    RVK:
    VA 4550
    Language: English
    Publisher: The Japan Institute of Heterocyclic Chemistry
    Publication Date: 1999
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Predicting Clinical Outcome in Patients with Idiopathic Thrombocytopenic Purpura Based on Bone Marrow Clot CD20+ Lymphocytes.
    American Society of Hematology ; 2006
    In:  Blood Vol. 108, No. 11 ( 2006-11-16), p. 3954-3954
    Details
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 3954-3954
    Abstract: The clinical outcome in patients with idiopathic thrombocytopenic purpura (ITP) is variable, while the factors at the time of diagnosis that predict the clinical outcome are unknown. Several studies have suggested that B-lymphocytes have an important role in the etiology of ITP (Jiang and Li 1995, van der Harst, et al 1990, Stasi, et al 2001), however the pathology of bone marrow clot CD20+ lymphocytes has not well described. Thus, we investigated whether pathological findings of bone marrow clot CD20+ lymphocytes at diagnosis could predict clinical outcome of the patients with ITP. We retrospectively reviewed the medical records of 73 ITP patients with platelet counts of & lt; 50 x 109/L who were newly diagnosed in Toyohashi Municipal Hospital between January 1997 and June 2005. In 56 patients, bone marrow clots at diagnosis were available for pathological review. The patient who was clinically diagnosed as having other cause of thrombocytopenia was excluded. We defined a complete response (CR) as a platelet count of at least 150 x 109/L within 13 weeks after completion of therapy and a partial response (PR) as a doubling of the initial platelet count or a platelet count above 50 x 109/L. All pathological examinations were performed in a blinded fashion; a single experienced pathologist retrospectively reviewed all stored bone marrow clots without knowing the patients’ clinical characteristics and outcomes. The median age of 56 patients was 65 years (range; 16–86). Thirty-nine patients were treated with prednisolone, and 17 patients were not treated. After primary treatment, CR to the treatment was achieved in 25 patients, and PR was achieved in 14 patients. Without treatment, spontaneous CR and PR occurred in 3 and 4 patients, respectively. In pathological findings, 43 of 56 patients have ≥1% CD 20+ lymphocytes among the nucleated cells. This pathological finding was a significant prognostic factor for treatment response; patients with ≥1% CD 20+ lymphocytes were more likely to not have a CR than patients with & lt;1% CD 20+ lymphocytes (odds ratio, 0.18; 95%, confidence interval, 0.04–0.91, p value, 0.04) in multivariate analysis. We suggested that the clinical outcome of ITP patients could be determined by evaluating bone marrow clot CD20+ lymphocytes. Potential prognostic factors for treatment response Prognostic factor for complete response Prognostic factor for any treatment response Factors Odds ratio 95% confidence interval P value Odds ratio 95% confidence interval P value ITP indicates idiopathic thrombocytopenic purpula. Gender (female vs. male) 1.16 0.31–4.36 0.83 2.46 0.51–11.81 0.26 Age (≥65 vs. & lt;65 years) 2.54 0.60–10.74 0.20 1.79 0.41–7.73 0.44 Primary treatment (0.5 mg/kg of PSL vs. no therapy) 5.80 1.12–30.13 0.04 5.96 1.23–29.03 0.03 Primary treatment (1 mg kg of PSL vs. no therapy) 63.01 4.34–914.83 0.002 52.01 2.05–1317.06 0.02 Hemoglobin ( & gt;10 vs.≤10 g/dl) 3.88 0.46–32.33 0.21 4.03 0.20–83.31 0.37 CD20+ lymphocytes in bone marrow (≥1% vs. & lt;1% of nucleated cells) 0.18 0.04–0.91 0.04 0.17 0.02–1.31 0.09
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    URL: Article
    DOI: 10.1182/blood.V108.11.3954.3954
    RVK:
    XA 33000
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Exchange of International Staging System for Durie&Salmon Staging System in Therapeutic Strategy for Multiple Myeloma.
    American Society of Hematology ; 2005
    In:  Blood Vol. 106, No. 11 ( 2005-11-16), p. 5167-5167
    Details
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 5167-5167
    Abstract: Introduction: Since multiple myeloma (MM) is not a curative disease and clinical outcome is variable, chemotherapy is started only when patients developed organ impairment or progression of disease. As for clinical staging, Durie & Salmon (DS) system is in use. The International Staging System (ISS) for MM has been recently reported to provide simple and useful prognostic grouping (Greipp et al. 2005). However, its usefulness in therapeutic strategy has not been clearly demonstrated. Patients and methods: We reviewed medical records of patients with MM, newly diagnosed in Toyohashi Municipal Hospital between May 1997 and April 2004. They were all stratified based on both ISS and DS system. Results: The median age of 55 patients was 67 years (range; 46–86). M protein isotypes included IgG (n=33), IgA (n=13), BJP (n=6) and IgD (n=1). Fifty-two patients were treated with chemotherapy and 12 of those patients underwent autologous peripheral blood stem cell transplantation. The median follow-up of the patients was 26.8 months (range; 1.4–77.5). Their staging and overall survival (OS) are summarized on the following table. ISS predicted OS more clearly than DS system in our study. Overall survival based on ISS and DS system ISS DS stage no. of patients OS at 3 yrs no. of patients OS at 3 yrs I 14 1.00 3 0.67 II 22 0.55 20 0.79 III 19 0.25 32 0.40 p-value 0.0102 0.3287 Thirteen of the 14 patients with ISS stage I are alive at median months of 31.5 (10.4–73.8), and only one patient died of secondary malignancy at 44.9 months from diagnosis. The patients with ISS stage I included 86% of DS stage II and III patients, who are usually required treatment. Conclusions and discussions: ISS could predict clinical outcome more clearly than DS system. The patients’ prognosis was good in ISS stage I although many patients with DS stage II and III was included in this group. We suggests that early treatment to the patients with ISS stage I might not be necessarily required. Further studies are needed to adopt ISS instead of DS system in therapeutic strategy. Figure Figure
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    URL: Article
    DOI: 10.1182/blood.V106.11.5167.5167
    RVK:
    XA 33000
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Clinical Characteristics and Outcomes in Patients with t(8;21) Acute Myeloid Leukemia in Japan.
    American Society of Hematology ; 2007
    In:  Blood Vol. 110, No. 11 ( 2007-11-16), p. 4269-4269
    Details
    In: Blood, American Society of Hematology, Vol. 110, No. 11 ( 2007-11-16), p. 4269-4269
    Abstract: Clinical characteristics of Japanese patients with t(8;21) acute myeloid leukemia (AML) have not been well described. From January 2000 to December 2005, a total of 147 Japanese adult de novo AML (FAB: M2) patients were newly diagnosed with t(8;21) AML (n=46) or without t(8;21) AML (n=101) in collaborating hospitals. Patients with t(8;21) (median age, 49.5 years; range, 18–86 years) were significantly younger than AML(M2) patients without t(8;21) (median age, 60 years; range 17–90 years) (p 〈 0.001). Three-year overall survival rate in patients with t(8;21) was 70% (95% confidence interval (CI), 51–83%), significantly better than that in AML (M2) patients without t(8;21) (log-rank test, p=0.005) (Figure). Among patients 〈 60-years-old, overall survival rates of patients with t(8;21) AML and patients with non-t(8;21) AML(M2) were 71% (95%CI, 47–86%) and 58% (95%CI, 41–72%), respectively (log-rank test, p=0.28). Of the 40 patients who achieved complete remission, 21 patients received high-dose cytarabine-containing consolidation therapy. Event-free survival rates at 3 years after diagnosis in patients with and without high-dose cytarabine were 60% (95%CI, 36–78%) and 57% (95%CI, 26–79%), respectively (log-rank, p=0.87). In multivariate analysis, age and white blood cell count at diagnosis represented significant predictors of overall survival. For the 147 AML(M2) patients, presence of t(8;21) was not a significant predictor of overall survival after adjusting for age (hazard ratio, 0.65; 95%CI, 0.34–1.24; p=0.19). Japanese patients with t(8;21) AML display more favorable survival rates than those in Western countries. Efficacy of high-dose cytarabine might differ between Japanese and Western patients. Clinicians must be aware of potential differences among different ethnicities. Figure Figure
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    URL: Article
    DOI: 10.1182/blood.V110.11.4269.4269
    RVK:
    XA 33000
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...